Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The future of renoprotection.

Norberto Perico1, Igor Codreanu, Arrigo Schieppati

  • 1Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo-Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy.

Kidney International. Supplement
|July 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lysinuric Protein Intolerance: Not Only a Disorder for Pediatric Nephrologists - Case Report.

Nephron·2024
Same author

Exploring the Clinical and Genetic Landscape of Angelman Syndrome: Patient-Reported Insights from an Italian Registry.

Journal of clinical medicine·2024
Same author

[Drugs for rare diseases: the blessing of being orphans.]

Recenti progressi in medicina·2019
Same author

Orphan drugs - Authors' reply.

Lancet (London, England)·2019
Same author

Outrageous prices of orphan drugs: a call for collaboration.

Lancet (London, England)·2018
Same author

BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2017

Chronic kidney diseases are a growing global health concern. Renoprotection strategies, including lifestyle changes and renin-angiotensin system blockade, aim to prevent kidney function decline and reduce the need for dialysis.

Area of Science:

  • Nephrology
  • Public Health

Background:

  • Chronic kidney diseases (CKDs) represent a significant and increasing global health burden.
  • Renal replacement therapy (dialysis, transplantation) is crucial for end-stage renal disease (ESRD) but strains healthcare budgets.
  • Preventing the progression of CKD to ESRD is a key clinical and policy objective.

Purpose of the Study:

  • To explore renoprotective strategies for interrupting or reversing progressive renal fibrosis and function loss.
  • To evaluate the role of proteinuria in CKD progression and the effectiveness of current therapeutic approaches.

Main Methods:

  • Review of experimental evidence linking proteinuria to interstitial inflammation and fibrosis.
  • Analysis of clinical studies correlating urinary protein excretion with glomerular filtration rate decline in various nephropathies.

Related Experiment Videos

  • Assessment of renin-angiotensin system blockade (ACE inhibitors, ARBs) as a primary renoprotective therapy.

    • Main Results:

    • Proteinuria is a key driver of interstitial inflammation, fibrosis, and progressive loss of renal function.
    • Clinical data confirm the experimental link between proteinuria and accelerated decline in glomerular filtration rate (GFR).
    • Renin-angiotensin system blockade effectively reduces proteinuria and slows GFR decline, but complete remission is infrequent, especially with late intervention.

    Conclusions:

    • Renoprotection strategies are vital to mitigate the rising incidence of CKD and ESRD.
    • Multimodal approaches, including lifestyle modifications (e.g., smoking cessation) and optimized pharmacotherapy, are necessary for patients unresponsive to initial treatments.
    • A concerted, evidence-based, multisectorial approach is essential for global renoprotection efforts.